ABBOTT LABORATORIES (ABT) vs. BOSTON SCIENTIFIC CORP (BSX) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

ABBOTT LABORATORIES (ABT) vs. BOSTON SCIENTIFIC CORP (BSX) Stock Comparison & Valuation | Edwyn

Updated 2026-04-15 16:30 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

ABT is trading ~21.8% below a BSX-implied P/E, supported by stronger scale, ROIC and lower leverage, but slower revenue growth and a weak Piotroski score limit conviction for a clear buy.

Actionable Takeaway

If you believe ABT's slower revenue growth will reaccelerate or the market will re-rate large-cap, higher-ROIC healthcare names toward BSX multiples, then consider buying ABT (ABT near $123.34) because it trades ~21.8% below BSX-implied P/E while exhibiting stronger ROIC and lower leverage; if growth disappoints or quality metrics (Piotroski F-Score) remain weak, hold or avoid.

ABT trades at $101.26 versus a BSX-implied price of $123.34 (21.8% upside), reflecting a P/E discount to BSX. Valuation on EV/EBITDA and EV/Revenue also shows ABT cheaper than BSX, supporting the case for a relative rerating if growth or multiple expansion materializes.

Supporting Metrics

Key Risks

Revenue growth shortfall: ABT Revenue Growth is only 5.7% versus BSX 19.9%, which could keep the multiple capped.
Weak fundamental momentum: Piotroski F-Score is 4/9, indicating limited improvement in key accounting/operational signals.
Lower gross margin: ABT Gross Margin 56.4% versus BSX 69.0% could indicate structural mix or cost disadvantages that constrain margin expansion.